Significantly reduces irritability
Does not disturb sleep cycles.
No weaning like other vibrations.
Prapela's SVS solution for Neonatal Abstinence Syndrome awarded NIDA grant.
The grant award from the NIH/National Institute on Drug Abuse will accelerate the research and commercialization of the Prapela SVS hospital bassinet pad to treat newborns diagnosed with neonatal abstinence syndrome. SVS is a patented, non-habit forming vibration with peer-review publications reporting it improves breathing, heart rate and relaxation in newborns diagnosed with NAS. Prapela is so grateful to so many organizations that have helped the company accelerate availability of SVS including: Children’s National Health System, Johnson & Johnson, The State of Ohio and its Third Frontier Program, the Charles H. Hood Foundation, the Southwest National Pediatric Device Consortium along the FDA funded Pediatric Device Consortium program.
$25,000 award to advance efforts with Neonatal Abstinence Syndrome (NAS)
Prapela was selected as a winner in the SW National Pediatric Device Consortium (SWPDC) program sponsored by Impact Pediatric Health (IPH) at SXSW. The $25,000 award will be used to help accelerate Prapela's efforts using its SVS technology to improve the clinical course of opioid-exposed newborns. The Prapela SVS hospital bassinet pad for use to treat neonatal abstinence syndrome is under development and will be the company's first product developed for hospital use.
Prapela's SVS solution for Neonatal Abstinence Syndrome wins $200,000 in the Ohio Opioid Technology Challenge.
The Challenge aims to identify technology-based solutions that address the opioid epidemic and create high-tech jobs at the same time. Prapela is now eligible for the next phase of the Challenge which will award $1,000,000 to participants that make significant progress advancing their ideas into reality.